Dr Eng. Dariusz Brzeziński, scientist of the Institute of Computer Science of the Poznań University of Technology is a co-author of the work on the mechanism of transport of dexamethasone in the blood and its possible impact on the treatment of COVID-19 patients.

The researcher from Poznań worked with scientists from the University of Virginia School of Medicine, University of South Carolina and the Medical University of Białystok. Scientists have determined how a protein in our blood, called serum albumin, takes dexamethasone and carries it to where it is needed. Low serum albumin levels are considered a major risk factor.

A new discovery regarding the transport of dexamethasone, (a drug that can increase the chances of survival for patients with severe COVID-19), suggests that diabetes and other factors could reduce its potentially life-saving effectiveness. Based on their findings, the researchers say doctors may need to rethink the dosing of the drug for specific groups of patients.